

# Contents

## Part I Fundamentals

<b>Setting up a Kinase Discovery and Development Project. . . . .</b>	<b>3</b>
Gideon Bollag	
<b>Drug Efficacy Testing in Mice . . . . .</b>	<b>19</b>
William Y. Kim and Norman E. Sharpless	

## Part II Kinase Targets and Disease

<b>Gastrointestinal Stromal Tumors . . . . .</b>	<b>41</b>
Cristina Antonescu	
<b>EGFR Mutant Lung Cancer . . . . .</b>	<b>59</b>
Yixuan Gong and William Pao	
<b>Targeting Oncogenic BRAF in Human Cancer . . . . .</b>	<b>83</b>
Christine A. Pratilas, Feng Xing and David B. Solit	
<b>Beyond BRAF in Melanoma . . . . .</b>	<b>99</b>
Adil Daud and Boris C. Bastian	
<b>JAK-Mutant Myeloproliferative Neoplasms . . . . .</b>	<b>119</b>
Ross L. Levine	
<b>Will Kinase Inhibitors Make it as Glioblastoma Drugs? . . . . .</b>	<b>135</b>
Ingo K. Mellinghoff, Nikolaus Schultz, Paul S. Mischel and Timothy F. Cloughesy	

**Part III Perspectives**

**Predictive Genomic Biomarkers** . . . . . 173  
Rakesh Kumar and Rafael G. Amado

**Epigenetic Biomarkers** . . . . . 189  
Timothy A. Chan and Stephen B. Baylin

**Adjuvant Trials of Targeted Agents: The Newest Battleground  
in the War on Cancer** . . . . . 217  
Robert L. Cohen

**Index** . . . . . 233